2017 Fiscal Year Final Research Report
An effect of the combination of oncolytic adenoviruses and a tyrosine-kinase inhibitor.
Project/Area Number |
16K21639
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Respiratory organ internal medicine
Biological pharmacy
|
Research Institution | Chiba Cancer Center (Research Institute) |
Principal Investigator |
Morinaga Takao 千葉県がんセンター(研究所), がん治療開発グループ, 研究員 (30757000)
|
Project Period (FY) |
2016-04-01 – 2018-03-31
|
Keywords | 悪性中皮腫 / 遺伝子治療 / アデノウイルス / チロシンキナーゼ / 細胞周期 |
Outline of Final Research Achievements |
Malignant mesothelioma is an intractable disease; thereby, development of innovative new drugs, which has a non-traditional strategy for cancer treatment is required. We focused on effectiveness of oncolytic adenoviruses on mesothelioma and further explored a drug that can strengthen the antitumor effect of the viruses. Our results suggested that a Wee1 kinase inhibitor could enhance the replication of adenoviruses and augment the cytotoxicity induced by the viruses through the apoptotic pathway.
|
Free Research Field |
分子腫瘍生物学
|